Lv11
36 积分 2024-02-23 加入
Oral PCSK9 Inhibitors: Can Novel Therapies Overcome Barriers to Effective LDL Cholesterol Management?
5小时前
已完结
NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines
12天前
已完结
Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children
1个月前
已完结
A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice
2个月前
已完结
High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes
3个月前
已完结
Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells
5个月前
已完结
New Pharmacological Approaches to Target PCSK9
5个月前
已完结
PCSK9-directed therapies: an update
5个月前
已完结
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
5个月前
已完结
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
5个月前
已完结
皖公网安备34019202002308
